PRN: Global Epinephrine Autoinjector Market (2017-2021) - By Dosage, Age Group & End User - Research-and-Markets

21/mar/2017 17:00:44 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Epinephrine Autoinjector Market (2017-2021) - By Dosage, Age Group & End User - Research-and-Markets

 
[21-March-2017]
 

DUBLIN, Mar 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Epinephrine Autoinjector Market 2017-2021" report to their offering.

Research and Markets Logo

The global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.

The report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is tentative product launches. The US market is forecasted to witness a number of product launches during the forecast period, due to the increased government's pressure on the FDA to approve more generic products of epinephrine autoinjectors.

According to the report, one of the major drivers for this market is increasing prevalence of allergies. The prevalence of allergies to food items, food additives, latex, and dust and the associated anaphylaxis has been increasing worldwide. On average, 30-35% of the global population is diagnosed with an allergy annually. This was initially seen in countries such as the UK, other countries in Europe, and the US, but it is now common in all industrially developed countries.

Further, the report states that one of the major factors hindering the growth of this market is product recalls and regulatory issues. The global epinephrine autoin! jector market has continuously faced hindrance owing to the periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Mylan monopoly.

Key vendors:

  • ALK-Abelló
  • Impax Laboratories
  • Lincoln Medical
  • Mylan

Other prominent vendors:

  • Adamis Pharmaceuticals
  • Antares Pharma
  • Emerade
  • Hospira
  • Kaleo Pharma
  • Teva Pharmaceutical Industries

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by dosage

PART 07: Market segmentation by age group

PART 08: Market segmentation by end-user

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/nqhdl4/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl